Background And Aim Of The Study: The study aim was to evaluate the durability of the new Mitroflow 12A pericardial bioprosthesis and to assess ventricular mass regression after aortic valve replacement (AVR) in patients with small valves.
Methods: A total of 326 Mitroflow 12A pericardial bioprostheses was implanted without any other associated valve procedure. The mean patient age was 73.5 +/- 6.1 years; 252 patients (78.0%) were in NYHA class III/IV. Small valves (19 and 21 mm) were implanted in 212 patients (65.6%). The total follow up period was 837.1 patient-years (pt-yr). A subset of 61 patients with preoperative stenosis was selected and submitted to conventional echo-Doppler assessment at a mean period of 11.1 months after surgery.
Results: Hospital mortality was 8.6%. At eight years of follow up, survival was 57.1%. Freedom from structural valve deterioration (SVD) was 86.5% per pt-yr. Mean gradients were significantly reduced postoperatively for each valve size (to 18 +/- 8 mmHg for 19-mm valves and 12 +/- 4 mmHg for 25-mm valves). The effective orifice area (EOA) was also increased significantly for all valve sizes (to 1.1 +/- 0.1 cm2 for 19-mm valves and 1.8 +/- 0.2 cm2 for 25-mm valves). The left ventricular mass index (LVMI) decreased significantly, from 177 +/- 29 to 136 +/- 22 g/m2 for the 19-mm valve, and from 200 +/- 42 to 132 +/- 22 g/m2 for the 25-mm valve. The EOA index (EOAI) showed mismatch for the 19- and 21-mm valves (0.74 and 0.82 cm2/m2, respectively). The diagrammatic calculation between LVMI and relative wall thickness after surgery showed that 29.7% of patients achieved a normal pattern of remodeling (including 19- and 21-mm valves), despite various degrees of mismatch.
Conclusion: The new Mitroflow 12A pericardial bioprosthesis showed an absence of mechanical failure after an eight-year follow up, with a satisfactory rate of SVD. Significant reductions in LVMI and improved ventricular geometry were observed, despite the small valve sizes implanted.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
The pathology of early failure in Mitroflow pericardial valve bioprosthesis (12A/LX).
Cardiovasc Pathol
December 2021
Department of Cardiac, Thoracic, Vascular Sciences and Public Health, Cardiovascular Pathology, University of Padua Medical School, Padua, Italy. Electronic address:
Background: Limited mid-term durability of 12A/LX Mitroflow bioprosthesis has been reported. Aim of the study was to ascertain the pathologic substrates and possible mechanisms of structural valve deterioration in explants from animals and humans.
Methods: Nine aortic 12A/LX Mitroflow bioprostheses preserved in hypotonic solution and three aortic 12A/LX bioprostheses, preserved in isotonic solution, were explanted from juvenile sheep, mean time from implant 95.
Structural valve deterioration of bioprosthetic aortic valves: An underestimated complication.
J Thorac Cardiovasc Surg
April 2019
INSERM UMR 1246 - SPHERE for Nantes University, Tours University, Tours, France; Center for Research in Transplantation and Immunology, Institute of Transplantation Urology and Nephrology, St Herblain, France.
Objectives: Structural valve deterioration (SVD) remains a major bioprosthesis-related complication, as recently described for the Mitroflow valve (models LX and 12A) (LivaNova, London, United Kingdom). The real incidence of the SVD risk remains unclear, often due to methodologic pitfalls by systematically using the Kaplan-Meier estimator and/or the Cox model. In this report, we propose for the first time a precise statistical modeling of this issue.
View Article and Find Full Text PDFFate of aortic bioprostheses: An 18-year experience.
J Thorac Cardiovasc Surg
March 2016
Department of Thoracic and Cardiovascular Surgery, "Dupuytren" University Hospital, Limoges, France.
Objective: To report our experience in aortic valve replacement with the Mitroflow (Sorin, Vancouver, Canada) aortic bioprosthesis.
Methods: We retrospectively reviewed all patients who underwent aortic valve replacement with a Mitroflow bioprosthesis at our institution from January 1994 to December 2011. No exclusion criteria were retained.
Early structural valve deterioration of Mitroflow aortic bioprosthesis: mode, incidence, and impact on outcome in a large cohort of patients.
Circulation
December 2014
From the Department of Thoracic and Cardiovascular Surgery (T.S., S.P., M.M., A.M., C.P., H.F.C., O.A.H., O.B., J.C.R.), Institut du Thorax (T.S., T.L.T., S.P., C.C., M.M., A.M., C.P., H.F.C., O.A.H., O.B., J.C.R.), Department of Cardiology (T.L.T., C.C.), and Department of Radiology (J.S.), University Hospital, Nantes, France; Member of Translink European Network (dedicated to structural valve deterioration) (T.S., T.L.T., C.C., J.C.R.); INSERM UMR1087, Nantes, France (T.L.T.); and EA 4275 SPHERE (BioStatistics, Pharmacoepidemiology & Human SciEnces REsearch), University of Nantes, Nantes, France (T.S., Y.F.).
Background: Structural valve deterioration (SVD) is a major flaw of bioprostheses. Early SVD has been suspected in the last models of Mitroflow bioprosthesis. We sought to assess the incidence, mode, and impact of SVD on outcome in a large series of Mitroflow aortic valve replacement.
View Article and Find Full Text PDFLeft ventricular mass regression after aortic valve replacement with the new Mitroflow 12A pericardial bioprosthesis.
J Heart Valve Dis
May 2006
Area Cardiovascular Department, Hospital Clínico Universitario, Santiago de Compostela, Spain.
Background And Aim Of The Study: The study aim was to evaluate the durability of the new Mitroflow 12A pericardial bioprosthesis and to assess ventricular mass regression after aortic valve replacement (AVR) in patients with small valves.
Methods: A total of 326 Mitroflow 12A pericardial bioprostheses was implanted without any other associated valve procedure. The mean patient age was 73.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!